Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

被引：8
|
作者：
Schellens, J. H. M.
Shapiro, G.
Pavlick, A. C.
Tibes, R.
Leijen, S.
Tolaney, S. M.
Diaz-Padilla, I.
Ramanathan, R. K.
Demuth, T.
Viscusi, J.
Cheng, J. D.
Lam, R.
Xu, Y.
Oza, A. M.
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] NYU, Ctr Canc, New York, NY USA
[4] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[6] Merck & Co Inc, N Wales, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3068
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
    Todd M. Bauer
    Kathleen N. Moore
    Janet S. Rader
    Fiona Simpkins
    Alain C. Mita
    J. Thaddeus Beck
    Lowell Hart
    Quincy Chu
    Amit Oza
    Anna V. Tinker
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Ganesh Mugundu
    Suzanne Jenkins
    Juliann Chmielecki
    Suzanne Jones
    David Spigel
    Siqing Fu
    Targeted Oncology, 2023, 18 : 517 - 530
  • [22] A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
    Bauer, Todd M.
    Moore, Kathleen N.
    Rader, Janet S.
    Simpkins, Fiona
    Mita, Alain C.
    Beck, J. Thaddeus
    Hart, Lowell
    Chu, Quincy
    Oza, Amit
    Tinker, Anna V.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh
    Jenkins, Suzanne
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David
    Fu, Siqing
    TARGETED ONCOLOGY, 2023, 18 (04) : 517 - 530
  • [23] Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
    Krop, Ian
    Demuth, Tim
    Guthrie, Tina
    Wen, Patrick Y.
    Mason, Warren P.
    Chinnaiyan, Prakash
    Butowski, Nicholas
    Groves, Morris D.
    Kesari, Santosh
    Freedman, Steven J.
    Blackman, Samuel
    Watters, James
    Loboda, Andrey
    Podtelezhnikov, Alexei
    Lunceford, Jared
    Chen, Cong
    Giannotti, Maxine
    Hing, Jeremy
    Beckman, Robert
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) : 2307 - 2313
  • [24] Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C β-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer
    Rademaker-Lakhai, Jeany M.
    Beerepoot, Laurens V.
    Mehra, Niven
    Radema, Sandra A.
    van Maanen, Rianne
    Vermaat, Joost S.
    Witteveen, Els O.
    Visseren-Grul, Carla M.
    Musib, Luna
    Enas, Nathan
    van Hal, Gertjan
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Voest, Emile E.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4474 - 4481
  • [25] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial
    Gatz, Susanne A.
    Harttrampf, Anne C.
    Brard, Caroline
    Bautista, Francisco
    Andre, Nicolas
    Abbou, Samuel
    Rubino, Jonathan
    Rondof, Windy
    Deloger, Marc
    Ruebsam, Marc
    Marshall, Lynley V.
    Huebschmann, Daniel
    Nebchi, Souad
    Aerts, Isabelle
    Thebaud, Estelle
    De Carli, Emilie
    Defachelles, Anne Sophie
    Paoletti, Xavier
    Godin, Robert
    Miah, Kowser
    Mortimer, Peter G. S.
    Vassal, Gilles
    Geoerger, Birgit
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 741 - 753
  • [27] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Falchook, Gerald S.
    Sachdev, Jasgit
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Jenkins, Suzanne
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Johnson, Melissa
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 493 - 502
  • [28] Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors.
    Schwartz, GK
    Kaubisch, A
    Saltz, L
    Ilson, D
    O'Reilly, E
    Barazzuol, J
    Endres, S
    Stoltz, M
    Tong, W
    Kelsen, DP
    Spriggs, D
    CLINICAL CANCER RESEARCH, 1999, 5 : 3754S - 3754S
  • [29] Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
    Giaccone, G
    González-Larriba, JL
    van Oosterom, AT
    Alfonso, R
    Smit, EF
    Martens, M
    Peters, GJ
    van der Vijgh, WJF
    Smith, R
    Averbuch, S
    Fandi, A
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 831 - 838
  • [30] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Gerald S Falchook
    Jasgit Sachdev
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Ganesh M Mugundu
    Suzanne Jenkins
    Juliann Chmielecki
    Suzanne Jones
    David R Spigel
    Melissa Johnson
    Investigational New Drugs, 2023, 41 : 493 - 502
12345